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Developing comparative effectiveness
studies for a rare, understudied pediatric
disease: lessons learned from the CARRA
juvenile localized scleroderma consensus
treatment plan pilot study
Suzanne C. Li1,2* , Robert C. Fuhlbrigge3 , Ronald M. Laxer4, Elena Pope4, Maria F. Ibarra5, Katie Stewart6,
Thomas Mason II7, Mara L. Becker8, Sandy Hong9, Fatma Dedeoglu10, Kathryn S. Torok11, C. Egla Rabinovich8,
Polly J. Ferguson12, Marilynn Punaro6, Brian M. Feldman4, Tracy Andrews13, Gloria C. Higgins14 and For the CARRA
Registry Investigators

Abstract
Background: We designed and initiated a pilot comparative effectiveness study for juvenile localized scleroderma
(jLS), for which there is limited evidence on best therapy. We evaluated the process we used, in relation to the
specific protocol and to the general task of identifying strategies for implementing studies in rare pediatric diseases.
Methods: This was a prospective, multi-center, observational cohort study of 50 jLS patients initiating treatment,
designed and conducted by the jLS group of the Childhood Arthritis and Rheumatology Research Alliance (CARRA)
from 2012 to 2015. A series of virtual and physical meetings were held to design the study, standardize clinical
assessments, generate and refine disease activity and damage measures, and monitor the study. Patients were
initiated on one of three standardized methotrexate-based treatment regimens (consensus treatment plans, CTPs)
and monitored for 1 year. An optional bio-banking sub-study was included.
Results: The target enrollment of 50 patients was achieved over 26 months at 10 sites, with patients enrolled into
all CTPs. Enrolled patients were typical for jLS. Study eligibility criteria were found to perform well, capturing
patients thought appropriate for treatment studies. Minor modifications to the eligibility criteria, primarily to
facilitate recruitment for future studies, were discussed with consensus agreement reached on them by the jLS
group. There were marked differences in site preferences for specific CTPs, with half the sites treating all their
patients with the same CTP. Most patients (88%) completed the study, and 68% participated in the bio-banking
substudy.
(Continued on next page)
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Conclusions: We demonstrate the feasibility of our approach for conducting comparative effectiveness research in
a rare pediatric disease. Multi-center collaboration by dedicated investigators who met regularly was a key factor in
the success of this project. Other factors that facilitate these studies include having a sufficient number of investigators
to enroll in each regimen, and streamlining study approval and management.
Keywords: Juvenile localized scleroderma, Comparative effectiveness trial, Study design, Consensus treatment plan,
Methotrexate, Corticosteroids, Assessment tools

Background
Pediatric rheumatology encompasses many diseases, which
vary greatly in their clinical features, prevalence, and pathophysiology. Identifying effective therapies for patients with
rare and complex disorders is challenging, requiring collaborative effort and innovative trial design [1–4]. Juvenile
localized scleroderma (jLS) is a rare pediatric rheumatic disease, with an estimated annual incidence of 1–3 per 100,000
children [5, 6]. Within the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy
registry of pediatric rheumatology patients in North America, 386 patients with jLS were enrolled between 2010 and
2014 compared to 6607 with juvenile idiopathic arthritis,
1217 with childhood systemic lupus erythematosus, and 688
with juvenile dermatomyositis [7, 8].
Lack of consensus on methods of assessment, logistical
difficulties in enrollment, and limited funding are among
the factors making randomized clinical treatment trials
(RCT) difficult in rare childhood rheumatic diseases. As
an alternate way to advance knowledge of best care,
CARRA has endorsed and supported comparative effectiveness research studies [3]. This method of prospective
observational research allows multiple centers to collectively study patient outcomes during the course of routine patient care, enabling a larger number and wider
range of patients to be studied at a lower cost than the
typical RCT. In this type of design, statistical analyses
that account for potential confounders are key. Comparative effectiveness research also allows optimized regimens of commonly used treatments for rare diseases to
be reliably compared to newer medications. With these
goals in mind, consensus treatment plans (CTPs) and
pilot comparative effectiveness studies have been developed and published by CARRA investigators for several
diseases including systemic juvenile idiopathic arthritis
and systemic lupus proliferative nephritis [3, 9, 10]. The
process we used to develop and implement a pilot comparative effectiveness study in jLS may be useful as a
model for implementing such studies in other rare
diseases.
Treatment of jLS is particularly difficult to study because of variability in clinical subtypes (including plaque
morphea, linear scleroderma, Parry Romberg syndrome,

pansclerotic morphea, and mixed forms), lesion severity
and location, and the character and severity of extracutaneous manifestations (including joint contractures, hemiatrophy of limbs, facial hemiatrophy, ocular dysfunction,
and seizures) [11–13]. Although schemata to measure skin
changes in jLS have been developed and validated [14],
training is required to establish accuracy and reliability of
scoring features such as skin thickening [15].
Treatments for pediatric rheumatic diseases are typically
studied in adults before being investigated in children. However, major differences between adult and juvenile onset localized scleroderma, including subtype predominance,
frequency and character of extracutaneous manifestations, and typical disease duration indicate that
pediatric-specific trials are needed [13]. While there is
evidence of shared pathogenesis between LS and
systemic sclerosis (SSc) [16, 17], optimal treatment
for SSc has also not been determined, and it is far
from certain that best treatment for jLS would be the
same.
Variations in perceived severity and prognosis can also
lead to variations in clinical care, making retrospective
analysis of efficacy difficult or impossible. Although there
are numerous case series in the literature supporting use
of methotrexate (MTX) with or without corticosteroid
(CS) for jLS, there is only one multicenter, double-blinded
RCT in which methotrexate was shown to be superior to
placebo. One significant aspect of this study is that all 70
patients were concurrently treated with oral prednisone
for the first 3 months, regardless of treatment arm [18]. A
survey of North American pediatric rheumatologists indicated agreement on the use of MTX as the systemic treatment of choice for jLS; however, recommended doses,
routes and regimens varied widely with 58 different MTX
regimens suggested for the same linear scleroderma of the
limb case vignette [19, 20]. Most responders also included
an initial course of CS, but again there was a lack of consensus on dose, route, and duration with 59 different corticosteroid regimens suggested for the linear scleroderma
case vignette [19, 20]. Clearly, more standardization of
even commonly used treatments is necessary for treatment efficacy research in jLS to proceed, and was the motivation for development of this CARRA pilot jLS CTP.
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The overall goals of this pilot study were to test the
methodology for a larger comparative effectiveness study
of jLS within CARRA, and to demonstrate the feasibility
of a larger study. The current manuscript describes only
part of the CTP pilot study; namely, the planning process,
development and post-study evaluation of enrollment criteria, success of enrollment as related to problems with
study initiation, the persistence of patients in the study,
the three treatment plans, and the standardization of clinical assessment tools for data collection. Subsequent manuscripts will focus on the findings of the study including
demographics of participants, performance of the clinical
assessments, response to treatments, and quality of life
measures.

Methods
Aim and study design

The jLS workgroup of CARRA has been working to
optimize treatment strategies for juvenile localized scleroderma, with comparative effectiveness studies viewed as a
possible means for accomplishing this task. To evaluate the
feasibility of conducting comparative effectiveness studies of
jLS and other rare pediatric diseases, and identify strategies
for implementing such studies, the jLS workgroup conducted a pilot prospective, multi-center, observational cohort study of 50 juvenile LS patients with active disease
between 2012 and 2015. The CARRA Legacy Registry was
used to house the data. Given the nature of the pilot, the
relative rarity of the disease, and the size of the patient
population treated at the participating institutions, a sample
of 50 patients, enrolled over 12 months, was considered to
be adequate to demonstrate feasibility and evaluate the data
collection methods and assessment tools created by the
study investigators [21, 22]. The data collected by this pilot
was intended to allow determination of whether a larger,
more comprehensive study could be conducted, to inform
the sample size calculation for such a study, and to determine how the study assessments and data collection could
be improved. The patient eligibility criteria for this study
are detailed in Table 1, with LS subtypes defined by Padua
criteria [23].
Study meetings

Fifteen investigators (14 pediatric rheumatologists and
1 pediatric dermatologist from 10 CARRA sites in the
US and Canada) were involved in the development
and conduct of this study. All participated in a series
of virtual and physical meetings to complete the
study design, develop standardized activity and damage measures, and generate disease assessment tools.
An initial face-to-face meeting was held in May 2012,
where the case report forms (CRFs) were finalized
and a workshop was conducted to standardize clinical
assessment among the participating investigators. Dr.
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Thomas Medsger Jr., an authority in scleroderma, led
a training session on skin thickness scoring with adult
patient volunteers. A reliability and validity study of
the cutaneous activity and damage measures developed for this project was conducted using 13 jLS patient volunteers. A discussion was held at the end of
the workshop to address scoring questions.
Monthly teleconference meetings were held throughout the period of the study to enhance site involvement
and enrollment, ensure consistency of study procedures, and assess and remedy problems as they arose.
The PI (SL) offered two call times in most months, in
order to accommodate the schedules of all investigators, and distributed summaries of the discussions to all
investigators. Nine additional face-to-face meetings were
held before, during and after the study, mostly occurring at
the annual meetings of CARRA and/or the American
College of Rheumatology, which the majority of study investigators attend on an annual basis. A final face-to-face
meeting was held in May 2015 to evaluate the performance
of developed criteria and measures, based upon available
study data.
Development of disease assessment tools

To conduct successful comparative effectiveness studies,
highly sensitive disease assessment tools are needed to
identify potentially small but significant differences in the
relative efficacy of treatment regimens under study. Since
there is a large variation in the availability of expert assessment using technology-based tools (such as the computerized skin score, infrared thermography, laser Doppler
flow, Doppler ultrasound, and magnetic resonance imaging) among centers worldwide (reviewed in [24, 25]), we
decided to use a manual assessment tool that could be
taught to pediatric rheumatologists and dermatologists.
Two previously described LS severity measures, LoSSI
and mLoSSI, served as basis for development of the
assessments used in this study [14, 26, 27]. Additional variables were added based upon their identification as activity variables in another CARRA jLS group prospective
study [28]. All of these studies were discussed by the
investigators to define the cutaneous measures for use in
this study, with ≥ 80% consensus required for all items.
During the study, the investigators developed a morbidity measure to capture extracutaneous involvement, with
the intention that the measure could then be tested on the
study data. Part of the rationale for developing this measure was to more accurately capture active disease, as some
extracutaneous features such as arthritis and uveitis represent disease activity. Case scenarios with photos derived
from actual patients, surveys, and the 1000minds
technique (https://www.1000minds.com/) were used to
generate scoring weights for this measure, with ≥ 80%
consensus required for all items.
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Table 1 Working jLS Study Entry Criteria: Inclusion, Exclusion,
and Active Disease criteria
Inclusion Criteria:
1. Localized scleroderma diagnosed by a Pediatric Rheumatologist
or Pediatric Dermatologist according to Padua Preliminary
Classification
criteria; these criteria exclude eosinophilic fasciitis [23]
2. Fulfill active disease criteria:
a. Either at least one item from Active disease criteria Group 1,
or two from Group 2
3. Moderate to high disease severity that warrants systemic therapy
in the opinion of the treating physician
a. Includes all subtypes that involve deeper tissue, extensive skin
involvement, and/or extracutaneous involvement
4. Age < 18 years at onset of disease
5. Age < 21 years at onset of treatment
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Table 1 Working jLS Study Entry Criteria: Inclusion, Exclusion,
and Active Disease criteria (Continued)
5. Worsening hair loss in scalp, eyebrow, or eyelashes; documented
by cliniciana
6. Elevated creatine kinase level in the absence of other sourcea
7. Lesion biopsy showing active disease (based upon
pathologist report. Typically would be presence of lymphocytes,
plasma cells, eosinophils, or other white blood cell)
Study entry criteria used for the jLS Consensus Treatment Plan (CTP)
Pilot study
These criteria were previously developed [20] for the purpose of directing
comparative effectiveness studies in jLS and were not intended to qualify or
disqualify patients for any specific treatment. The LS Scoring Atlas was
generated by the LS workgroup of CARRA and contains photographs of
patient lesions demonstrating the different visible scored features; > 80%
consensus agreement by workgroup members was required for the
photograph to be included in the atlas [20]
a
denotes criteria that were modified or deleted as a result of this study—see
Table 2

Exclusion criteria:
1. Treated with systemic corticosteroids in the prior 2 weeks
2. Treated with methotrexate or mycophenolate mofetil within
the prior 3 monthsa
3. Another defined systemic rheumatic disease (e.g., systemic
sclerosis)
4. Intolerance to study medications
Working Active Disease criteria (used for Pilot Consensus Treatment
Plan study)a
Group 1:
1. New lesion(s) within the prior 3 months, documented by
cliniciana
2. Extension of an existing lesion within the prior 3 months,
documented by cliniciana
a. Lesion extension observed in serial photographs or tracings,
or detecting > 30% difference in lesion size (maximum length x width).
3. Documentation of active or progressive deep tissue involvementa
a. Can be by clinical examination, photographs, MRI, or ultrasound
4. Erythema of moderate or severe level in lesion or an erythematous
lesion border
a. Erythema scoring level based upon LS Scoring Atlas
5. Violaceous lesion or border color
a. Can range from lilac ring to deep violaceous color
Group 2:
1. Patient or parent report of new lesion OR extension of existing
lesion occurring within the prior 3 monthsa
a. This criterion ONLY applies for new patients (i.e., first visit to
clinician’s office).
2. Erythema of mild level
a. Erythema scoring level based upon LS Scoring Atlas
3. Moderate or severe induration of lesion bordera
a. Assessed according to modified Rodnan Skin Scoring (mRSS)
levels [15]
4. Tactile warmth of the lesion
a. Examiner appreciation of temperature difference based
upon comparison to control site (unaffected contralateral site if
available).

To increase standardization of scoring, with parent/patient permission we developed an atlas of photographs
(scoring atlas) demonstrating all scoring levels for each
visually scored lesion features, including those on different Fitzpatrick skin tone types. At numerous on-line and
face-to-face meetings, investigators discussed and came
to consensus agreement on which photos to include in
the atlas [20]. Face-to-face meetings were used to review
modules of the extracutaneous measures developed to
confirm consensus agreement, train investigators on use,
and to review photos relevant to the scoring variables
for inclusion in the scoring atlas.
Treatment plans

We studied 3 methotrexate-based CTPs, designed according to best available evidence, current treatment practices
of CARRA members, and consensus methodology [20].
The three CTPs all utilized the same weekly dose of
methotrexate (1 mg/kg/weekly dose, maximum 25 mg),
with subcutaneous dosing preferred. The CTPs were:
methotrexate monotherapy (CTP A), methotrexate with
intravenous CS (CTP B, pulse methylprednisolone either
once weekly for the first 12 weeks or on three consecutive
days per month for the first 3 months, each dose 30 mg/kg
with a maximum of 1000 mg/dose); methotrexate with
oral CS (CTP C, prednisone or prednisolone, initial 2 mg/
kg/day, maximum 60 mg, divided bid for 2–4 weeks, then
tapered to 1 mg/kg/day divided bid by 8 weeks, 0.5 mg/kg/
day by 16 weeks, 0.25 mg/kg/day by 24 weeks, and off by
48 weeks). There was no plan for tapering or discontinuing methotrexate, as it was intended to be continued
throughout the study. Folic or folinic acid supplementation was recommended. The choice of CTP was made
jointly by the participating parent/patient and physician
(Fig. 1). Since this was an observational study rather than
a treatment trial, physicians could change treatment during the study as considered appropriate. Patients were
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Fig. 1 Screen failure and CTP selection reasons. Reasons for screen failures: There was a total of 23 screen failures, with 12 patients not meeting
inclusion or meeting exclusion criteria, and 11 not consented for other reasons. “Not feasible” refers to family not consenting because of visit
schedule or travel time required to reach to study site. Reasons for choice of CTP: The number of patients treated with each of the CTPs is shown
in bold text below the CTP. The physician and patient/family jointly decided upon which CTP to use, and could choose more than one reason
for their selection. The reasons for CTP selection are listed, and in the same row the corresponding number (%) of patients enrolled for each
reason within each of the three CTPs is shown. Not shown are concerns about patient compliance (n = 1, CTP B, 4%), or insurance issues (n = 0).
CTP: consensus treatment plan; IV CS: intravenous corticosteroid (methylprednisolone); jLS: juvenile localized scleroderma; mo: month; MTX:
methotrexate; n: number of patients; rx: treatment; PO CS: oral corticosteroid (prednisone or prednisolone)

labeled as drop-outs if they withdrew their consent for
study participation, did not return for or have study forms
completed at follow-up study visits, or self-discontinued
study medications before the 9- month visit. Patients were
labeled as having a major deviation from the study protocol if they discontinued the study medication for more
than 2 weeks, or used a systemic immunomodulator that
was not included in the CTP. The latter type of major deviation was considered also to be a treatment failure (the
requirement of additional systemic immunomodulator
other than specified by their starting CTP).

Study visits

To avoid inter-rater scoring variability, a given patient
was evaluated by the same physician at all study visits.
Data collection was performed during regular clinic
visits at baseline, and at 2, 4, 6, 9, and 12 months, with a
recommended window of +/− 1 month, following initiation of treatment. We planned this large visit window
to improve study retention and reduce scheduling difficulties associated with conducting research in busy
clinics. Skin activity scoring (modified localized scleroderma severity index [mLoSSI] [14, 29] and localized
scleroderma cutaneous activity measure [LSCAM], a

measure developed by CTP study group [20]) and physician global assessment of disease activity (PGA-A) were
collected at each study visit. Skin damage scoring, PGADamage, morbidity scoring, and health related quality of
life (HRQoL) measures were captured at 0, 6, and 12
month visits. Collected HRQoL assessments included visual analog or Likert scale questions, PedsQL™ generic,
PedsQL™ rheumatology, PedsQL™ Family Impact, childhood dermatology life quality index, and childhood health
assessment questionnaire [30–34].
All study participants were entered into the CARRA
Legacy Registry, which captured standard information
common to pediatric rheumatic diseases, and the majority of scored LS variables. Study data not captured in the
Legacy registry were entered into a dedicated electronic
database to evaluate the new assessment tools and criteria, and to determine the necessary minimum data set.
Using the second database limited the expense associated with use of CARRA Legacy Registry, while enabling
capture and testing of all study items.

Biobanking

For optional biobanking, blood was collected at study entry,
6 months, and 12 months. Specimens were processed for
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serum, plasma, peripheral blood mononuclear cells, RNA
and DNA, and stored at University of Pittsburgh for future
study of disease markers. Phlebotomy and shipping supplies
were provided by the University of Pittsburgh.
Regulatory and contract requirements

This study was conducted within the CARRA Legacy registry, with contracting required at each site with the Duke
Clinical Research Institute for site payment for data and
blood collection. Data identified only by subject number
were analyzed at Hackensack University Medical Center,
the coordinating center, under ethics approval number for
Pro00001481. Individual participating centers obtained
their own ethics/institutional review board approvals to enroll patients and collect specimens. Informed consent/
assent was obtained per site protocol, and no compensation
was given to participants.
Statistical analysis

Descriptive statistics were used to summarize data on study
enrollment and contract completion, study visit times, and
evaluate active disease criteria. Detailed patient characteristics, adequacy of sample size, CTP performance, and treatment outcomes will be presented in separate manuscripts.

Results
Study enrollment

All 15 investigators from the 10 sites enrolled patients
(1–9 per site). All patients fulfilled inclusion criteria and
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did not fulfill any exclusion criteria, as defined in Table 1.
IRB and contract approval for the first site occurred at 10
months, and for the final site at the 17th month
following study initiation (Fig. 2). Enrollment was completed within 16 months following the first site approval, and within 9 months following the final site
approval. Thus, due to administrative delays, full enrollment was not achieved until 26 months from study initiation, and we did not meet our initial goal of full
enrollment within 1 year .
Of 73 total patients screened, 23 were not enrolled; 12
because the patient was not eligible (Fig. 1). The most
common reason for ineligibility was use of MTX within
the past 3 months (n = 5). (During this interval, at least
two patients were having a disease flare while off MTX
but could not be enrolled.) Another 11 patients met inclusion criteria but were not enrolled, most commonly because of study visit schedule and/or travel distance (n = 5),
or because of patient and/or parent refusal (n = 4). One
patient/parent refusal was because the family wanted to
be treated with a lower dose of MTX than specified in the
CTPs; the other 3 were for unstated reasons, with sites
queried but unable to furnish additional information.
There were no screen failures related to physician preference for a non-CTP treatment regimen.
The general demographics of enrolled patients was
similar to published pediatric LS cohorts, with the majority being female (70%), white (92%), and non-Hispanic
(82%) [13]. Forty-one of the 50 enrolled patients (82%)

Fig. 2 Study enrollment time course: time to obtain site contracts and complete patient enrollment. The black circles show the cumulative
number of patients enrolled by month of the study period, with time 0 equal to the start of the grant-funding period. Work on the research
study approval and contracts began 4 months before the start of grant funding. The grey open circles show the number of sites with completed
study approvals and contracts at each month. The first research study approval and contract completion occurred in the 10th month, with the
last occurring at the 17th month

Li et al. Pediatric Rheumatology

(2019) 17:43

Page 7 of 12

Fig. 3 Activity criteria for study inclusion. To be eligible for the study, patients had to fulfill at least 1 criterion from Group 1, or at least 2 criteria
from Group 2 (see Table 1). The X axis indicates the number of patients, with the number of patients who fulfilled each criterion shown at the
end of each bar. Overall 42 (84%) of patients fulfilled at least 1 of the Group 1 criteria, many of whom also fulfilled Group 2 criteria. Eight (16%) of
patients fulfilled only Group 2 criteria. “New lesion” appears in both groups: In Group 1, new lesion must have been documented by physician or
physician review of patient photographs. In Group 2, new lesion was not documented by physician, but was reported by patient/parent. “Erythema”
appears in both groups: In Group 1, erythema is moderate-severe; In Group 2, erythema is mild

had new onset jLS. The remaining 9 had received systemic
therapy for jLS in the past and presented with relapse of
disease off treatment. Although enrollment of these previously treated patients may have increased the heterogeneity of treatment responses, comparison of efficacy of the
different CTPs was not a primary goal.
Performance of active disease criteria

Previously developed active disease criteria for eligibility
in a treatment study (Table 1 [20]) were evaluated in this
pilot study (Fig. 3). The active disease criteria consist of
two categories of features with active disease defined by
the presence of a single feature from Group 1, or two or
more features from Group 2. All screened patients considered appropriate to treat with systemic immunosuppressants fulfilled at least one active disease criteria
group (Group 1 or Group 2, Table 1). Forty-two (84%) of
patients fulfilled Group 1 criteria, while 8 (16%) fulfilled
only Group 2. The most commonly fulfilled criteria were
erythema and new lesion for both groups (Fig. 3). No
significant differences were found between patients who
fulfilled Group 1 versus those who fulfilled only Group 2
criteria for physician global assessment of disease activity

(4 vs. 6, respectively), baseline LS cutaneous activity
measure score (6.5 vs. 4), disease duration (15 month vs.
11.5 months), or disease subtype (mostly linear for both
groups).
Initial enrollment into the three CTPs: reasons for choice

Investigators enrolled patients in all three of the CTPs
(Figs. 1 and 4). Not surprisingly, individual site investigators
showed strong preferences in choice of CTP (Fig. 4). Nine
of 10 centers used only 1 or 2 of the treatment plans available. The most common reason for MTX monotherapy
(CTP A) selection was concerns about adverse events,
followed by “works best” and “better tolerated.” The most
common reason for selection of a corticosteroid and MTX
therapy (CTP B or C) was also that it “works best” (Fig. 1).
Persistence in the study

During the trial, 44 (88%) of the participants remained in
the study, while 6 (12%) were considered drop-outs. Reasons for dropping out included the family doubting the
need or effectiveness of treatment resulting in withdrawal
from the study (n = 1) or stopping the medication before
the 9 month study visit (n = 1), data not being collected
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Fig. 4 CTP selection by study site. The CTPs selected for the study patients at each study site are shown. Each of the 10 participating CARRA sites
is indicated by a different number following the letter “S” (S1-S10). The columns show the number of patients enrolled into each CTP at each site.
At 5 sites, all of the study patients at the site were treated with the same CTP, while at four sites two CTPs were used. Only one site (S8) used all
three CTPs for treating study patients. CTP: Consensus Treatment Plan; MTX: methotrexate; IV CS: intravenous corticosteroid (methylprednisolone);
oral CS: oral corticosteroid (prednisone or prednisolone)

after the baseline visit due to not being recognized as a
study patient at a satellite clinic [n = 1], patient switching
care to a non-study physician, either an adult rheumatologist or pediatric rheumatologist located closer to the family (n = 2), and unknown (n = 1, site queried but unable to
furnish reason for drop-out.).
Most participants completed either 5 or 6 of the six
scheduled visits (74%). The proportion completing 4, 3, 2,
or 1 visit were 10, 4, 2, and 6% respectively. Seventy-nine
percent of visits were completed within the 1 month of
target window. Completion of the study was defined as
the patient remaining on prescribed treatment and completing at least the 9-month visit. Based on this definition,
88% of patients completed the study.
Post-study evaluation of eligibility criteria

A more critical evaluation of the performance of the inclusion and exclusion criteria (Table 1) was conducted near
the end of the study to determine if there should be any
modifications for their use in future studies. All modifications for future studies required agreement by ≥ 80% of
the investigators. Based on this review, elevated CK was
eliminated as an active disease criterion because it was
rarely selected and assignment of etiology was considered
potentially problematic. Several criteria for active disease
were combined to make a single criterion for disease extension to simplify use of the criteria (Table 2, italics, compare to Table 1). The presence of a waxy white or yellow
lesion was added as a criterion (Table 2) because it was
identified as an active feature in another prospective study
[28], but since data analysis for that study was not finished

until the after this CTP pilot was already underway, we
chose not to add waxy white or yellow as an activity criterion during the course of the CTP. We have tested its association with active disease in the CTP data set, which will
be described in a subsequent manuscript.
In addition, the group decided to shorten the required
wash-out time after treatment with MTX or mycophenolate from 3 months to 1 month for entry into future studies.
The impetus behind this decision was the observation that
at least 2 patients followed by the investigators experienced
recurrence of active disease 1–2 months after stopping
MTX but could not be enrolled in the study. Pharmacokinetic studies have shown that MTX polyglutamates in red
blood cells have elimination half-lives of ranging from 1.2–
4.3 weeks, with median times for MTX polyglutamates to
become undetectable ranging from 4 to 10 wks [35]. Thus,
it appeared likely that some patients may flare quickly following discontinuation of MTX. Based on the known
pharmacokinetics of MMF, showing an even shorter average elimination half-life for mycophenolic acid (8.5 h) and
its glucuronide 13 h) [36], we opted to use 1 month as our
minimum washout time for MMF as well. The revised eligibility criteria recommended for future jLS treatment studies
are shown in Table 2, with italics indicating changes as
compared to Table 1.
Biobanking

Thirty-six (72%) participants/parents consented to biobanking. All three requested samples were collected for 21
patients, 2 samples for 7 patients, and 1 sample for 8 patients. Reasons for failure to complete collection of
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Table 2 Revised jLS Study Entry Criteria: Inclusion, Exclusion,
and Active Disease criteria
Inclusion Criteria:
1. Localized scleroderma diagnosed by a Pediatric Rheumatologist or Pediatric
Dermatologist according to Padua Preliminary Classification criteria; these criteria
exclude eosinophilic fasciitis [23]
2. Fulfill active disease criteria:
a. Either at least one item from Active disease criteria Group 1
or two from Group 2
3. Moderate to severe disease severity that warrants systemic therapy
in the opinion of the treating physician
a. Includes all subtypes that involve deeper tissue(s), extensive skin
involvement, and/or extracutaneous involvement
4. Age < 18 years at onset of disease
5. Age < 21 years at onset of treatment
Exclusion criteria:
1. Treated with systemic corticosteroids in the prior 2 weeks
2. Treated with methotrexate or mycophenolate mofetil within the
prior 4 weeks
3. Another defined systemic rheumatic disease (e.g., systemic sclerosis)
4. Intolerance to study medications
Revised Active Disease criteria
Group 1:
Developing comparative effectiveness studies
1. New, larger, or deeper lesion that developed within the past 3 months
associated with erythema, violaceous color, and/or skin thickening. Disease
extension must be documented by one of the following
a. Clinical exam
b. Measurements or tracings
c. Photographs (may be provided by family)
d. Imaging: MRI, ultrasound, CT, 3D imager
2. Erythema of moderate or severe level
a. Erythema scoring level based upon LS scoring atlas
3. Violaceous color
a. Can range from lilac ring to deep violaceous color
Group 2:
1. Erythema of mild level
a. Erythema scoring level based upon LS scoring atlas
2. Waxy white or yellow lesion
a. These lesions have white or yellowish appearance with smooth,
waxy feeling
b. They are associated with skin thickening (induration)
3. Skin thickening of lesion
a. Assessed according to modified Rodnan Skin Scoring (mRSS)
levels [15]
4. Tactile warmth of the lesion
a. Examiner appreciation of temperature difference based upon
comparison to control site (unaffected contralateral site if available).
5. Worsening hair loss on scalp or face
6. Inflammation within lesion identified on tissue biopsy
Revised entry criteria for jLS treatment studies. Modifications of the criteria used for
the jLS Consensus Treatment Plan (CTP) Pilot study shown in Table 1; modified
criteria are shown in italics. These criteria are not intended to qualify or disqualify
patients for any specific treatment. The LS Scoring Atlas was generated by the LS
workgroup of CARRA and contains photographs of patient lesions demonstrating the
different visible scored features; ≥ 80% consensus agreement by workgroup
members was required for the photograph to be included in the atlas [20]
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biobanking samples included blood collection being done
at non-affiliated facilities per patient/family preference,
lack of facilities at satellite clinics to collect and process
samples for mailing, lack of study coordinators to attend
to specimen collection and processing, and inability to
draw labs at Friday clinics because the biobanking site
could not receive samples on a Saturday.

Discussion
We report here the successful development and enrollment of a pilot comparative effectiveness study for jLS, a
rare pediatric rheumatic disease for which there is no
proven best treatment regimen. In addition to assessing
feasibility, the purpose of this pilot study was to identify
how subsequent studies could be improved, and to evaluate new assessment tools. We reached our enrollment goal
of 50 jLS patients, and found that the demographics of
our study participants were typical for this disease. However, total enrollment time was 26 months, or more than a
year longer than expected, with contract issues being the
major reason for delay.
The high degree of agreement on the use of these
CARRA CTPs for treating jLS patients is demonstrated by
there being no screen failures related to physician preference for a non-CTP regimen for treatment. The limited
number of screen failures due to refusal demonstrates that
patients and parents are willing to participate in comparative effectiveness research, and the low drop-out rate (12%)
indicates that these CTPs were generally tolerable to patients and families. As with most clinical studies, the visit
and travel schedule precluded several patients from participating, and led some participants to miss study visits.
Nonetheless, a relatively high proportion of patients, 44 of
50 (88%), completed the study.
Bio-banked specimens aligned with detailed clinical information are valuable resources for future research in
disease pathogenesis and treatment, even more so in
rare diseases because they are so difficult to acquire. We
demonstrated that bio-banking is feasible in clinic-based
comparative effectiveness studies, though several centers
were unable to collect or ship specimens at all of the
assigned visits, for reasons as given in results. Of 36
patients who contributed to the optional biobanking
sub-study, only 21 (58%) provided all three samples per
protocol. It will be important in future studies to work
on reducing the logistic barriers to sample collection.
Nonetheless, the samples collected in this pilot are of
significant value to this community of investigators.
One aspect of comparative effectiveness research that
reduces barriers to enrollment is that investigators and
study patients can choose among standardized treatment
options. We noted that sites showed distinct preferences
in their choice of CTP, with half the sites treating all of
their study patients with the same CTP, and only one
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site using each of the three CTPs. Part of this lack of
variation in intra-center treatment choice may be due to
the small numbers enrolled by some centers. In the absence of definitive efficacy studies to provide guidance,
physicians may tend to base treatment decisions on their
own observational history and/or what they have been
taught, rather than on evidence of efficacy. In addition,
the rarity of jLS means that many physicians have limited experience with treating jLS. Given the lack of data
regarding comparative efficacy, the observation that the
reasons for selection of any of the three CTPs were “It
works best” or “It is what I/my group always does,” highlight the need for better data.
Our previously developed inclusion and exclusion criteria,
including activity criteria for eligibility in a treatment study,
seemed to perform well. However, post-study review and
consensus agreement led to some modifications of these criteria to potentially increase eligibility of patients to enroll in
future treatment studies, and to simplify their use (compare
Table 2 italicized text to Table 1).

Conclusions
We were able to design and fully enroll a pilot prospective,
multicenter, 1-year observational cohort study of three standardized methotrexate-based treatment regimens (CTPs)
for juvenile localized scleroderma, an uncommon and
understudied childhood disease. This pilot study allowed us
to evaluate the performance of the study inclusion and exclusion criteria, to propose modifications of those criteria,
and to consider protocol changes likely to improve future
treatment studies of jLS.
Specifically, “lessons learned” that will help with design
of further comparative effectiveness research appeared
to fall within the following four general categories:
(1) Investigator commitment and effective
communication: A committed, cohesive, and
enthusiastic group of investigators who are willing
to re-think pre-existing assumptions about
treatments and methods of evaluation, and who
participate in frequent, detailed, well-planned
meetings to discuss the protocol, are most likely to
be successful in designing and completing difficult
studies.
(2) Number and variability of participating
investigators/sites. Despite the lack of definitive
information, investigators showed strong
preferences in their treatment choices. Therefore,
it is important to have a sufficient number of
investigators with different treatment preferences
to adequately enroll in all treatment arms of a
comparative effectiveness study. It may be
advisable to survey investigators as to their
treatment preferences in advance to assess if
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additional investigators/sites are needed to ensure
a balanced distribution of patients across the
treatment arms.
(3) Support of professional organizations.
Encouragement, logistical and financial support,
and infrastructure from a larger organization were
extremely valuable for many aspects of this study,
including resources for collection and analysis of
data, and facilitating multiple face-to-face meetings
of the investigators. Other valuable support for this
study included standardization of biospecimen
collection and processing protocols to ensure
consistency of samples, and optimize their value for
future translational studies. As pediatric rheumatology
is a rare subspecialty, most pediatric rheumatology
centers have few providers and limited staff support,
so that backing and support from larger professional
organizations is important for the success of clinicbased studies.
(4) Institutional administrative challenges. We achieved
our target enrollment of 50 jLS patients, but
enrollment took more than a year longer than
expected due to contract issues with participating
medical institutions. Efficient and rational review
processes by individual or shared IRBs/Ethics
Committees and institutional contracts offices are
essential for timely enrollment in medical research
studies.
Our description of the elements that supported completion of this study, and some of the problems that we
encountered in the course of the study, may be of benefit to other clinicians wishing to develop comparative
effectiveness research studies for other rare diseases.
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